FIBROSARC did not meet its primary PFS endpoint in the final analysi
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Enabling a new era in minimally invasive obesity treatment across Europe
Relmada expects to initiate its Phase 3 program in the first half of 2026
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Subscribe To Our Newsletter & Stay Updated